Next Article in Journal
Dexpanthenol in Wound Healing after Medical and Cosmetic Interventions (Postprocedure Wound Healing)
Previous Article in Journal
Human Recombinant FSH and Its Biosimilars: Clinical Efficacy, Safety, and Cost-Effectiveness in Controlled Ovarian Stimulation for In Vitro Fertilization
Previous Article in Special Issue
Fighting Hypoxia to Improve PDT
Open AccessArticle

TLD1433-Mediated Photodynamic Therapy with an Optical Surface Applicator in the Treatment of Lung Cancer Cells In Vitro

1
Department of Cell Stress Biology, Photodynamic Therapy Center, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14203, USA
2
Department of Chemistry and Biochemistry, The University of Texas at Arlington, Arlington, TX 76019-0065, USA
3
Department of Chemistry and Biochemistry, The University of North Carolina at Greensboro, Greensboro, NC 27402-6170, USA
*
Authors to whom correspondence should be addressed.
Principal Investigators.
Pharmaceuticals 2020, 13(7), 137; https://doi.org/10.3390/ph13070137
Received: 21 May 2020 / Revised: 25 June 2020 / Accepted: 26 June 2020 / Published: 28 June 2020
(This article belongs to the Special Issue Photodynamic Therapy 2019)
Intra-operative photodynamic therapy (IO-PDT) in combination with surgery for the treatment of non-small cell lung cancer and malignant pleural mesothelioma has shown promise in improving overall survival in patients. Here, we developed a PDT platform consisting of a ruthenium-based photosensitizer (TLD1433) activated by an optical surface applicator (OSA) for the management of residual disease. Human lung adenocarcinoma (A549) cell viability was assessed after treatment with TLD1433-mediated PDT illuminated with either 532- or 630-nm light with a micro-lens laser fiber. This TLD1433-mediated PDT induced an EC50 of 1.98 μM (J/cm2) and 4807 μM (J/cm2) for green and red light, respectively. Cells were then treated with 10 µM TLD1433 in a 96-well plate with the OSA using two 2-cm radial diffusers, each transmitted 532 nm light at 50 mW/cm for 278 s. Monte Carlo simulations of the surface light propagation from the OSA computed light fluence (J/cm2) and irradiance (mW/cm2) distribution. In regions where 100% loss in cell viability was measured, the simulations suggest that >20 J/cm2 of 532 nm was delivered. Our studies indicate that TLD1433-mediated PDT with the OSA and light simulations have the potential to become a platform for treatment planning for IO-PDT. View Full-Text
Keywords: TLD1433; optical surface applicator; intra-operative photodynamic therapy; PDT; light simulation TLD1433; optical surface applicator; intra-operative photodynamic therapy; PDT; light simulation
Show Figures

Graphical abstract

MDPI and ACS Style

Chamberlain, S.; Cole, H.D.; Roque, J., III; Bellnier, D.; McFarland, S.A.; Shafirstein, G. TLD1433-Mediated Photodynamic Therapy with an Optical Surface Applicator in the Treatment of Lung Cancer Cells In Vitro. Pharmaceuticals 2020, 13, 137.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop